Tøstesen Michael, Østergård Lene S G, Kjeldsen Eigil, Stentoft Jesper, Nørgaard Jan M
Ugeskr Laeger. 2018 Jan 15;180(3).
Acute promyelocytic leukaemia has changed from being a highly fatal to a highly curable disease. Over time, key discoveries have identified the genetic and molecular abnormalities, which cause the disease. First choice of treatment has now changed from all-trans retinoic acid (ATRA) and chemotherapy to a chemo-free combination of arsenic trixoide and ATRA. This new regimen has shown equal responses and overall cure rates compared with the previous standard of care containing conventional chemotherapy, but with much lower toxicity. This will pave the way for better and easier treatment for elderly and frail patients.
急性早幼粒细胞白血病已从一种高致死性疾病转变为一种高治愈率疾病。随着时间推移，关键发现已明确了导致该疾病的基因和分子异常。目前，首选治疗方案已从全反式维甲酸（ATRA）和化疗转变为三氧化二砷与ATRA的无化疗联合方案。与包含传统化疗的先前标准治疗相比，这种新方案显示出相同的反应和总体治愈率，但毒性要低得多。这将为老年和体弱患者带来更好、更简便的治疗方法。
